FDA Approves First-Line Therapy for Advanced Bladder Cancer
The FDA has expanded its approval of atezolizumab (Tecentriq) for the treatment of advanced bladder cancer to include the initial therapy of patients who are not eligible for cisplatin chemotherapy.
Biomarkers Could Predict Bladder Cancer Progression
This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.
Avelumab Shows Promising Results in Advanced Urothelial Carcinoma
The PD-L1 antibody avelumab was well tolerated and had promising antitumor activity in patients with refractory metastatic urothelial carcinoma.
Maintenance Vinflunine Extends PFS in Advanced Urothelial Carcinoma
Maintenance vinflunine yielded longer progression-free survival vs best supportive care in advanced urothelial carcinoma patients after disease control with chemotherapy.
Sorafenib Plus Chemotherapy Promising in Muscle-Invasive Bladder Cancer
Sorafenib, gemcitabine, and cisplatin had promising activity and was well tolerated in patients with muscle-invasive urothelial bladder cancer.
Long-Term Data Confirm CRT Benefit in Muscle-Invasive Bladder Cancer
Long-term data from the phase III BC2001 trial confirmed that adding chemotherapy to radiation therapy improves locoregional control and reduces the rate of salvage cystectomy in patients with muscle-invasive bladder cancer.
Genomic Subtyping Could Guide Treatment Decisions for Bladder Cancer
Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.
Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.